HPV Vaccine – 2 or 3 Doses?

9-14 YEARS¹

2 DOSES

Routine: 11-12 years
As early as 9 years
Catch-up at 13-14 years

HPV9
Gardasil-9®

6–12 months²

HPV9
Gardasil-9®

15+ YEARS⁴ OR COMPROMISED IMMUNE SYSTEM³

3 DOSES

15–26 years⁴

OR

9–14 years with a compromised immune system³

HPV9
Gardasil-9®

1–2 months⁵

HPV9
Gardasil-9®

6 months between 1st and 3rd dose

HPV9
Gardasil-9®

Footnotes:
1. Vaccination as early as age 9 years is recommended for children with a history of sexual abuse or assault and an option for other children.
2. Minimum acceptable interval is 5 months.
3. Includes conditions that reduce cell-mediated or humoral immunity, such as B lymphocyte antibody deficiencies, T lymphocyte complete or partial defects, HIV infection, malignant neoplasms, transplantation, autoimmune disease, or immunosuppressive therapy. The recommendation for a 3 dose schedule does not apply to persons <15 years with asplenia, asthma, chronic granulomatous disease, chronic liver disease, chronic lung disease, chronic renal disease, central nervous system anatomic barrier defects (e.g., cochlear implant), complement deficiency, diabetes, heart disease, or sickle cell disease.
4. Includes females through age 26, males through age 21, men who have sex with men and transgender persons through age 26.
5. Minimum acceptable interval is 4 weeks between the 1st and 2nd dose and 12 weeks between the 2nd and 3rd dose.

Additional Notes:
- If the vaccination schedule is interrupted, the series does not need to be restarted.
- The number of recommended doses is based on age at administration of the first dose.
- HPV9 may be used to continue or complete a vaccination series started with 4vHPV or 2vHPV.

For more information, see: www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html
California Department of Public Health, Immunization Branch  www.EZIZ.org
This publication was supported by Grant Number H23/CCH922507 from the Centers for Disease Control and Prevention (CDC) IMM-1254 (10/17)